<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127122</url>
  </required_header>
  <id_info>
    <org_study_id>DB-EF-EXITARDS-0003</org_study_id>
    <nct_id>NCT05127122</nct_id>
  </id_info>
  <brief_title>Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial</brief_title>
  <acronym>EXIT-ARDS</acronym>
  <official_title>Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direct Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direct Biologics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of intravenous(IV) administration of bone marrow&#xD;
      mesenchymal stem cell derived extracellular vesicles(EV), ExoFlo, as treatment for Acute&#xD;
      Respiratory Distress Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of serious adverse events.</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>All-Cause Mortality at 28 days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days at 28days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Placebo Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</intervention_name>
    <description>Injectable</description>
    <arm_group_label>10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</arm_group_label>
    <arm_group_label>15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</arm_group_label>
    <other_name>ExoFlo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo Saline</description>
    <arm_group_label>Placebo Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form (either by the individual or by&#xD;
             the individual's healthcare proxy).&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female aged 18-85.&#xD;
&#xD;
          4. Moderate to severe ARDS as defined by modified Berlin definition (See Section 2.2.1),&#xD;
             which includes timing within 1 week of known clinical insult or new or worsening&#xD;
             respiratory symptoms; bilateral opacities not fully explained by effusions, or lung&#xD;
             collapse; respiratory failure not fully explained by cardiac failure or fluid&#xD;
             overload; PaO2/FiO2 â‰¤ 200 mm Hg.&#xD;
&#xD;
          5. Hypoxia requiring noninvasive oxygen support such as Nasal Cannula (NC), Nonrebreather&#xD;
             (NRB), Bilevel Positive Airway Pressure (BIPAP), Continuous Positive Airway Pressure&#xD;
             (CPAP), high flow nasal cannula oxygen (HFNC O2) or mechanical ventilation (MV)&#xD;
             despite initiating standard of care.&#xD;
&#xD;
          6. If the candidate is either a male or female of reproductive potential, he or she must&#xD;
             agree to use of double barrier method of highly effective birth control contraception&#xD;
             such as condoms with oral contraceptive pill or choose to remain abstinent if already&#xD;
             practicing abstinence during the screening period. The required duration of usage of&#xD;
             double barrier method OR maintenance of abstinence must include the time from the&#xD;
             beginning of the screening period until 90 days following the last dose of the study&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Vulnerable populations such as pregnant patients, children, individuals with severe&#xD;
             physical or mental disabilities who cannot provide meaningful consent.&#xD;
&#xD;
          2. Active malignancy requiring treatment within the last five years.&#xD;
&#xD;
          3. Major physical trauma in the last 2 days, including motor vehicle accidents, assaults,&#xD;
             mechanical falls with sequelae of significant bleeding or craniofacial bruising, and&#xD;
             surgeries, such that not one or more injury may be undiagnosed at time of screening.&#xD;
&#xD;
          4. Diagnosis or suspected diagnosis of sepsis without basic microbiology cultures&#xD;
             (urinalysis, urine culture, two sets of blood cultures, respiratory culture, at least&#xD;
             a standard respiratory viral panel PCR) being collected prior to screening. (Note:&#xD;
             Standard respiratory viral panel is defined by at least PCR testing for Adenovirus,&#xD;
             Influenza A, Influenza B, Parainfluenza 1-3, Rhinovirus/Enterovirus, and RSV.)&#xD;
&#xD;
          5. Duration of mechanical ventilation exceeds 5 days or 120 hours.&#xD;
&#xD;
          6. Severe pre-existing organ dysfunction prior to admission, as evidenced by being&#xD;
             currently listed on one or more organ transplant list, or intermittent Hemodialysis&#xD;
             (HD) or Peritoneal Dialysis.&#xD;
&#xD;
          7. Presence of severe hematologic disorder or coagulopathy, such as Disseminated&#xD;
             Intravascular Coagulopathy, as evidenced by the activation of a Massive Transfusion&#xD;
             Protocols (as defined by the rapid administration of packed Red Blood Cells, Fresh&#xD;
             Frozen Plasma and Platelets in fixed ratios, including at least 6 packed Red Blood&#xD;
             Cells, within a 24 hour period) within 72 hours or frequent thrombosis of catheters&#xD;
             (as specified by replacing 2 catheters or more within a 72 hour period of new&#xD;
             placement) within 72 hours.&#xD;
&#xD;
          8. Severe anemia or myelodysplastic syndrome requiring more than 10 units of packed Red&#xD;
             Blood Cells transfused within the last 12 months.&#xD;
&#xD;
          9. Patient is currently connected to Extracorporal Membrane Oxygenation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikram Sengupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Direct Biologics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi Moran</last_name>
    <phone>800-791-1021</phone>
    <email>hmoran@directbiologics.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ExoFlo</keyword>
  <keyword>EXIT-ARDS</keyword>
  <keyword>ARDS</keyword>
  <keyword>Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles</keyword>
  <keyword>Direct Biologics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

